Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, Setoain X, Rodríguez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jiménez-Ubieto A, Rodriguez A, González de Villambrosía S, Bello JL, López L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, González M, Martín A, Caballero MD, López-Guillermo A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO).

Br J Haematol. 2019 Feb 22. doi: 10.1111/bjh.15805. [Epub ahead of print]

PMID:
30793290
2.

Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma.

Navarro-Bailón A, Jiménez C, Alonso-Álvarez S, Alcoceba M, González-Calle V, Chillón MC, García-Álvarez M, Prieto I, Medina A, González M, Caballero MD, Blanco Ó, Díaz LG, García-Sanz R, Sarasquete ME.

Hematol Oncol. 2018 Dec 13. doi: 10.1002/hon.2570. [Epub ahead of print] No abstract available.

PMID:
30548996
3.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711. [Epub ahead of print] No abstract available.

PMID:
30322315
4.

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27.

5.

Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.

Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho JM, Gómez P, Bento L, Montoro J, Montes S, López A, Bosch F; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group).

Ann Hematol. 2018 Dec;97(12):2417-2424. doi: 10.1007/s00277-018-3473-8. Epub 2018 Aug 16.

PMID:
30116871
6.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B; Aristotle Consortium.

Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.

PMID:
30078408
7.

Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.

Criado I, Blanco E, Rodríguez-Caballero A, Alcoceba M, Contreras T, Gutiérrez ML, Romero A, Fernández-Navarro P, González M, Solano F, Gómez C, Pérez-Andrés M, van Dongen JJM, Almeida J, Orfao A; EuroFlow PID Group and The Primary Health Care Group of Salamanca for the Study of MBL.

Leukemia. 2018 Dec;32(12):2701-2705. doi: 10.1038/s41375-018-0164-3. Epub 2018 Jun 21. No abstract available.

8.

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.

Moreno MJ, Gallardo A, Novelli S, Mozos A, Aragó M, Pavón MÁ, Céspedes MV, Pallarès V, Falgàs A, Alcoceba M, Blanco O, Gonzalez-Díaz M, Sierra J, Mangues R, Casanova I.

PLoS One. 2018 Jun 19;13(6):e0198789. doi: 10.1371/journal.pone.0198789. eCollection 2018.

9.

Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome.

Criado I, Rodríguez-Caballero A, Gutiérrez ML, Pedreira CE, Alcoceba M, Nieto W, Teodosio C, Bárcena P, Romero A, Fernández-Navarro P, González M, Almeida J, Orfao A; Primary Health Care Group of Salamanca for the Study of MBL.

Haematologica. 2018 Jul;103(7):1198-1208. doi: 10.3324/haematol.2017.183954. Epub 2018 Mar 22.

10.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
11.

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

Jiménez C, Prieto-Conde MI, García-Álvarez M, Alcoceba M, Escalante F, Chillón MDC, García de Coca A, Balanzategui A, Cantalapiedra A, Aguilar C, Corral R, González-López T, Marín LA, Bárez A, Puig N, García-Mateo A, Gutiérrez NC, Sarasquete ME, González M, García-Sanz R.

Ann Hematol. 2018 Mar;97(3):475-484. doi: 10.1007/s00277-017-3207-3. Epub 2018 Jan 20.

PMID:
29353304
12.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2018 Oct;59(10):2318-2326. doi: 10.1080/10428194.2017.1397660. Epub 2017 Nov 8.

PMID:
29115891
13.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

14.

From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.

Jiménez C, Alonso-Álvarez S, Alcoceba M, Ordóñez GR, García-Álvarez M, Prieto-Conde MI, Chillón MC, Balanzategui A, Corral R, Marín LA, Gutiérrez NC, Puig N, Sarasquete ME, González M, García-Sanz R.

Blood Cancer J. 2017 Aug 25;7(8):e591. doi: 10.1038/bcj.2017.72.

15.

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E.

Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.

16.

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, Moreno M, Salar A, García-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Rodríguez A, Jiménez-Ubieto A, González de Villambrosia S, Bello JL, López L, Monsalvo S, Novelli S, de Cabo E, Infante MS, Pardal E, García-Álvarez M, Delgado J, González M, Martín A, López-Guillermo A, Caballero MD.

Br J Haematol. 2017 Sep;178(5):699-708. doi: 10.1111/bjh.14831. Epub 2017 Aug 7.

PMID:
28782811
17.

Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.

Chillón MC, Jiménez C, García-Sanz R, Alcoceba M, Prieto I, García-Alvarez M, Antón A, Maldonado R, Hernández-Ruano M, González M, Gutiérrez NC, Sarasquete ME.

Ann Hematol. 2017 Oct;96(10):1699-1705. doi: 10.1007/s00277-017-3083-x. Epub 2017 Aug 2.

PMID:
28770277
18.

Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone: A case report.

Cubo AM, Soto ZM, Cruz MÁ, Doyague MJ, Sancho V, Fraino A, Blanco Ó, Puig N, Alcoceba M, González M, Sayagués JM.

Medicine (Baltimore). 2017 May;96(19):e6846. doi: 10.1097/MD.0000000000006846.

19.

Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression.

Criado I, Muñoz-Criado S, Rodríguez-Caballero A, Nieto WG, Romero A, Fernández-Navarro P, Alcoceba M, Contreras T, González M, Orfao A, Almeida J; Primary Health Care Group of Salamanca for the Study of MBL.

Haematologica. 2017 Jul;102(7):1238-1246. doi: 10.3324/haematol.2016.159012. Epub 2017 Apr 6.

20.

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.

García-Álvarez M, Alcoceba M, López-Parra M, Puig N, Antón A, Balanzategui A, Prieto-Conde I, Jiménez C, Sarasquete ME, Chillón MC, Gutiérrez ML, Corral R, Alonso JM, Queizán JA, Vidán J, Pardal E, Peñarrubia MJ, Bastida JM, García-Sanz R, Marín L, González M.

PLoS One. 2017 Mar 1;12(3):e0172978. doi: 10.1371/journal.pone.0172978. eCollection 2017.

21.

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, García O, Moreno M, Pomares H, Alcoceba M, González-García E, Motlló C, González-Barca E, Martin A, Sureda A, Caballero D, Ribera JM, Sancho JM.

Hematol Oncol. 2017 Dec;35(4):520-527. doi: 10.1002/hon.2378. Epub 2017 Feb 3. Erratum in: Hematol Oncol. 2019 Feb;37(1):114.

PMID:
28156010
22.

Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone.

Alonso-Alvarez S, Redondo-Guijo A, Blanco Ó, Alcoceba M, Balanzategui A, Caballero JC, Dávila J, González M, Caballero MD, Martín A, García-Sanz R.

Case Rep Hematol. 2016;2016:3947510. Epub 2016 Oct 27.

23.

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R.

J Mol Diagn. 2017 Jan;19(1):99-106. doi: 10.1016/j.jmoldx.2016.08.004. Epub 2016 Nov 15.

PMID:
27863261
24.

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>.

Alonso-Álvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A, Peñarrubia MJ, Zato E, Galende J, Bárez A, Alcoceba M, Orfão A, González M, García-Sanz R.

Leuk Lymphoma. 2017 May;58(5):1144-1152. doi: 10.1080/10428194.2016.1239263. Epub 2016 Oct 12.

PMID:
27733075
25.

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.

Hematol Oncol. 2017 Dec;35(4):746-751. doi: 10.1002/hon.2337. Epub 2016 Sep 8.

PMID:
27605156
26.

MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.

Hernández-Sánchez M, Rodríguez-Vicente AE, Hernández JÁ, Lumbreras E, Sarasquete ME, Martín AÁ, Benito R, Vicente-Gutiérrez C, Robledo C, Heras Nde L, Rodríguez JN, Alcoceba M, Coca AG, Aguilar C, González M, Hernández-Rivas JM.

Leuk Res. 2016 Jul;46:30-6. doi: 10.1016/j.leukres.2016.04.008. Epub 2016 Apr 12.

PMID:
27111859
27.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

28.

High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.

Sebastián E, Alcoceba M, Martín-García D, Blanco Ó, Sanchez-Barba M, Balanzategui A, Marín L, Montes-Moreno S, González-Barca E, Pardal E, Jiménez C, García-Álvarez M, Clot G, Carracedo Á, Gutiérrez NC, Sarasquete ME, Chillón C, Corral R, Prieto-Conde MI, Caballero MD, Salaverria I, García-Sanz R, González M.

Ann Hematol. 2016 Jan;95(2):253-62. doi: 10.1007/s00277-015-2552-3. Epub 2015 Nov 14.

PMID:
26573278
29.

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

Puig N, Conde I, Jiménez C, Sarasquete ME, Balanzategui A, Alcoceba M, Quintero J, Chillón MC, Sebastián E, Corral R, Marín L, Gutiérrez NC, Mateos MV, González-Díaz M, San-Miguel JF, García-Sanz R.

Leukemia. 2015 Jun;29(6):1435-7. doi: 10.1038/leu.2015.7. Epub 2015 Jan 8. No abstract available.

PMID:
25567133
30.

Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?

Sánchez LA, Redondo AM, Muñez OB, Sebastián E, Alcoceba M, González M, Martín A, Caballero D.

Ann Hematol. 2015 Apr;94(4):609-16. doi: 10.1007/s00277-014-2256-0. Epub 2014 Dec 25.

PMID:
25537456
31.

CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.

Moreno MJ, Bosch R, Dieguez-Gonzalez R, Novelli S, Mozos A, Gallardo A, Pavón MÁ, Céspedes MV, Grañena A, Alcoceba M, Blanco O, Gonzalez-Díaz M, Sierra J, Mangues R, Casanova I.

J Pathol. 2015 Feb;235(3):445-55. doi: 10.1002/path.4446. Epub 2014 Dec 11.

PMID:
25231113
32.

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.

Jiménez C, Chillón Mdel C, Balanzategui A, Puig N, Sebastián E, Alcoceba M, Sarasquete ME, Conde IP, Corral R, Marín LA, Paiva B, Ruano M, Antón A, Maldonado R, San Miguel JF, González M, García-Sanz R.

Appl Immunohistochem Mol Morphol. 2014 Nov-Dec;22(10):768-73. doi: 10.1097/PAI.0000000000000020.

PMID:
24992174
33.

Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia.

González-Gascón Y Marín I, Hernández JA, Martín A, Alcoceba M, Sarasquete ME, Rodríguez-Vicente A, Heras C, de Las Heras N, Fisac R, García de Coca A, de la Fuente I, Hernández-Sánchez M, Recio I, Galende J, Martín-Núñez G, Alonso JM, Hernández-Rivas JM, González M.

Biomed Res Int. 2014;2014:257517. doi: 10.1155/2014/257517. Epub 2014 Mar 30.

34.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
35.

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R.

Br J Haematol. 2013 Oct;163(2):223-34. doi: 10.1111/bjh.12519. Epub 2013 Aug 16.

PMID:
23952215
36.

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R.

Leukemia. 2014 Feb;28(2):391-7. doi: 10.1038/leu.2013.217. Epub 2013 Jul 17.

PMID:
23860448
37.

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.

Alcoceba M, Sebastián E, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M.

Blood. 2013 Aug 22;122(8):1448-54. doi: 10.1182/blood-2013-02-483420. Epub 2013 Jul 10.

38.

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.

Jiménez C, Sebastián E, Chillón MC, Giraldo P, Mariano Hernández J, Escalante F, González-López TJ, Aguilera C, de Coca AG, Murillo I, Alcoceba M, Balanzategui A, Sarasquete ME, Corral R, Marín LA, Paiva B, Ocio EM, Gutiérrez NC, González M, San Miguel JF, García-Sanz R.

Leukemia. 2013 Aug;27(8):1722-8. doi: 10.1038/leu.2013.62. Epub 2013 Feb 28.

PMID:
23446312
39.

Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.

Sebastián E, Alcoceba M, Balanzategui A, Marín L, Montes-Moreno S, Flores T, González D, Sarasquete ME, Chillón MC, Puig N, Corral R, Pardal E, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M.

Am J Pathol. 2012 Nov;181(5):1879-88. doi: 10.1016/j.ajpath.2012.07.028. Epub 2012 Sep 11.

PMID:
22982190
40.

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillón MC, Sebastián E, Marín LA, Díaz MG, San Miguel JF, Sanz RG.

Ann Hematol. 2013 Jan;92(1):97-100. doi: 10.1007/s00277-012-1566-3. Epub 2012 Sep 7.

PMID:
22956183
41.

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillón MC, Sebastián E, Díaz MG, San Miguel JF, García-Sanz R.

Eur J Haematol. 2012 Oct;89(4):328-35. doi: 10.1111/ejh.12000. Epub 2012 Aug 25.

PMID:
22805350
42.

Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.

Chillón MC, Gómez-Casares MT, López-Jorge CE, Rodriguez-Medina C, Molines A, Sarasquete ME, Alcoceba M, Miguel JD, Bueno C, Montes R, Ramos F, Rodríguez JN, Giraldo P, Ramírez M, García-Delgado R, Fuster JL, González-Díaz M, Menendez P.

Leukemia. 2012 Nov;26(11):2360-6. doi: 10.1038/leu.2012.161. Epub 2012 Jun 18.

PMID:
22705992
43.

The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, van Loon J, de Vries L, Cavé H, Acquaviva C, Lawler M, Crampe M, Serra A, Saglio B, Colnaghi F, Biondi A, van Dongen JJ, van der Burg M, Gonzalez M, Alcoceba M, Barbany G, Hermanson M, Roosnek E, Steward C, Harvey J, Frommlet F, Bader P.

Leukemia. 2012 Aug;26(8):1821-8. doi: 10.1038/leu.2012.66. Epub 2012 Mar 7.

PMID:
22395360
44.

Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain).

Alcoceba M, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Martín-Jiménez P, Puig N, Santamaría C, Corral R, García-Sanz R, San Miguel JF, González M.

Tissue Antigens. 2011 Oct;78(4):249-55. doi: 10.1111/j.1399-0039.2011.01766.x.

PMID:
21929573
45.

Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeats.

van der Burg M, Kreyenberg H, Willasch A, Barendregt BH, Preuner S, Watzinger F, Lion T, Roosnek E, Harvey J, Alcoceba M, Díaz MG, Bader P, van Dongen JJ; EU-supported EuroChimerism Consortium project QLRT-2001-01485.

Leukemia. 2011 Sep;25(9):1467-70. doi: 10.1038/leu.2011.118. Epub 2011 Jun 17.

PMID:
21681189
46.

Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.

Sarasquete ME, Gutiérrez NC, Misiewicz-Krzeminska I, Paiva B, Chillón MC, Alcoceba M, García-Sanz R, Hernández JM, González M, San-Miguel JF.

Haematologica. 2011 Mar;96(3):468-71. doi: 10.3324/haematol.2010.033845. Epub 2010 Dec 15.

47.

Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.

Puig N, Caballero MD, Alcoceba M, Sebastián E, Balanzategui A, Sarasquete ME, García-Sanz R, González-Díaz M.

Ann Hematol. 2011 Feb;90(2):227-9. doi: 10.1007/s00277-010-0987-0. Epub 2010 May 27. No abstract available.

48.

Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.

Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M.

Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4.

49.

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M.

Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27.

PMID:
19943049
50.

Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation.

Santos-Briz A, Romo A, Antúnez P, Román C, Alcoceba M, Garcia JL, Vazquez L, González M, Unamuno P.

Clin Exp Dermatol. 2009 Dec;34(8):e778-81. doi: 10.1111/j.1365-2230.2009.03509.x. Epub 2009 Oct 10.

PMID:
19817764

Supplemental Content

Loading ...
Support Center